SCHEMBL20914267

SCHEMBL20914267

Cc1[nH]c2c(-c3ccccc3)c(C#N)nn2c(=O)c1-c1nc2ccc(N)cc2o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.38
▸ ALDH1A1 P00352 5/20 0.38
▸ MAPT P10636 5/20 0.38
▸ HPGD P15428 5/20 0.38
▸ NPC1 O15118 4/20 0.38
▸ RAB9A P51151 4/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ GLA P06280 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ CASP1 P29466 1/20 0.35
▸ P2RY6 Q15077 1/20 0.34
▸ GPR119 Q8TDV5 11/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ GFER P55789 1/20 0.33
▸ MGLL Q99685 1/20 0.33
▸ F2RL3 Q96RI0 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914318 0.93 RAB9A (0.41) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL20837037 0.89 P2RY6 (0.37) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL20914307 0.84 KDM4E (0.39) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL20914059 0.84 MAT2A (0.33) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL20837240 0.83 KMT2A (0.34) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL20837038 0.83 ADORA2A (0.34) KDM4EALDH1A1MEN1KMT2AF2RL3
SCHEMBL20914254 0.83 DAGLA (0.34) KDM4EALDH1A1HPGDNPC1RAB9A
SCHEMBL20913988 0.83 KMT2A (0.34) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL20913968 0.80 KDM4E (0.34) KDM4EALDH1A1MAPTHPGDMEN1
SCHEMBL20914241 0.80 MEN1 (0.42) KDM4EALDH1A1MAPTHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 KDM4E 1922/4885ALDH1A1 1246/4885MAPT 214/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 KDM4E 1922/4885ALDH1A1 1246/4885MAPT 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback